Jerome Durso Net Worth

Jerome Durso biography

Jerome Benedict Durso serves as Chief Operating Officer of the Company. Mr. Durso has over 25 years of experience in building and leading commercial and business operations at life sciences companies both in the United States and abroad. Prior to joining the Company, Mr. Durso served as a consultant to the biopharmaceutical industry from September 2015 to February 2017. Mr. Durso has spent the majority of his career at Sanofi, a global pharmaceutical company, where he most recently served as Senior Vice President, Chief Commercial Officer of the Global Diabetes Division from June 2011 to April 2015. From 2010 to 2011, Mr. Durso was Senior Vice President, Chief Commercial Officer of Sanofi’s U.S. pharmaceuticals business. Prior to that, he served in a number of commercial leadership roles of increasing responsibility in business unit and brand management, marketing and sales since he first joined Sanofi in 1993. Mr. Durso earned his bachelor’s degree in marketing from the University of Notre Dame.

What is the salary of Jerome Durso?

As the Chief Operating Officer of Intercept Pharmaceuticals Inc, the total compensation of Jerome Durso at Intercept Pharmaceuticals Inc is $4,281,790. There are 1 executives at Intercept Pharmaceuticals Inc getting paid more, with Mark Pruzanski having the highest compensation of $6,615,780.

How old is Jerome Durso?

Jerome Durso is 52, he's been the Chief Operating Officer of Intercept Pharmaceuticals Inc since 2017. There are 11 older and 9 younger executives at Intercept Pharmaceuticals Inc. The oldest executive at Intercept Pharmaceuticals Inc is Keith Gottesdiener, 66, who is the Independent Director.

What's Jerome Durso's mailing address?

Jerome's mailing address filed with the SEC is C/O INTERCEPT PHARMACEUTICALS, INC., 305 MADISON AVENUE, MORRISTOWN, NJ, 07960.

Insiders trading at Intercept Pharmaceuticals Inc

Over the last 12 years, insiders at Intercept Pharmaceuticals Inc have traded over $1,530,243,701 worth of Intercept Pharmaceuticals Inc stock and bought 2,408,920 units worth $77,118,364 . The most active insiders traders include Srinivas Akkaraju, Jonathan Silverstein, eFrancesco Micheli. On average, Intercept Pharmaceuticals Inc executives and independent directors trade stock every 10 days with the average trade being worth of $1,114,673. The most recent stock trade was executed by Srinivas Akkaraju on 10 March 2021, trading 237,000 units of ICPT stock currently worth $5,017,290.

What does Intercept Pharmaceuticals Inc do?

we are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (pbc), nonalcoholic steatohepatitis (nash), primary sclerosing cholangitis (psc) and biliary atresia. in a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-viral liver disease. we are committed to improving patients’ lives and addressing the liver community’s most pressing needs. our corporate headquarters is located in new york, and we have additional offices in san diego, london and perugia. for more information about intercept, please visit our website at: www.interceptpharma.com and follow us on twitter at: @interceptpharma.

Intercept Pharmaceuticals Inc executives and stock owners

Intercept Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Mark Pruzanski,
  President, Chief Executive Officer, Director
• Jerome Durso,
  Chief Operating Officer
• Ryan Sullivan,
  General Counsel, Secretary
• Richard Kim,
  President, U.S. Commercial & Strategic Marketing
• Sandip Kapadia,
  Chief Financial Officer, Treasurer
• Gail Cawkwell,
  Senior Vice President - Medical Affairs, Safety & Pharmacovigilance
• Lisa Bright,
  President, International
• David Ford,
  Chief Human Resource Officer
• Dr. Mark Pruzanski M.D.,
  Founder, Advisor & Director
• Jerome B. Durso,
  Pres, CEO & Director
• Paolo Fundaro,
  Independent Chairman of the Board
• Gino Santini,
  Lead Independent Director
• Glenn Sblendorio,
  Independent Director
• Daniel Welch,
  Independent Director
• Daniel Bradbury,
  Independent Director
• Luca Benatti,
  Independent Director
• Nancy Miller-Rich,
  Independent Director
• Keith Gottesdiener,
  Independent Director
• Srinivas Akkaraju,
  Independent Director
• Jason Campagna,
  Chief Medical Officer
• Christian Weyer,
  Executive Vice President - Research & Development
• Linda M. Richardson,
  Exec. VP & Chief Commercial Officer
• Jared M. Freedberg J.D.,
  Gen. Counsel
• Lisa M. DeFrancesco,
  Sr. VP of Corp. Affairs & Investor Relations
• Rocco Venezia,
  Chief Accounting Officer & Treasurer
• Bryan Ball,
  Chief Quality Officer & Sr. VP of Operations
• Andrew Saik,
  Chief Financial Officer
• Barbara Gayle Duncan,
  Chief Financial Officer
• Rachel Mc Minn,
  Chief Strategy Officer
• David Shapiro,
  Chief Medical Officer
• Linda M Richardson,
  EVP & Chief Commercial Officer
• S.P.A. Genextra,
  
• M Michelle Berrey,
  President, R&D and CMO
• Daniel Paul Regan,
  Chief Commerical Officer
• Jonathan Silverstein,
  Director
• Advisors Llc Orbi Med Capit...,
  
• Lorenzo Tallarigo,
  Director
• Klaus R Dr Veitinger,
  Director
• Sanj K Patel,
  Director
• Luciano Adorini,
  Chief Scientific Officer
• Nicole Williams,
  Director
• Francesco Micheli,
  
• Bryan Ball,
  Chief Qual. Officer & SVP Ops.
• Rocco Venezia,
  Chief Accounting Officer
• Dagmar Rosa Bjorkeson,
  Director
• Lisa De Francesco,
  SVP, IR & Corp. Affairs
• Jared Freedberg,
  General Counsel